ArticleInternational journal of clinical oncology2011
18F-FDG PET/MRI fusion in characterizing pancreatic tumors: comparison to PET/CT.
Article in International journal of clinical oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Imaging modalities for characterising focal pancreatic lesions.The Cochrane database of systematic reviews · 2017Pooled it
- The progress of PET/MRI in clinical management of patients with pancreatic malignant lesions.Frontiers in oncology · 2023Review
- Impact of PET/MRI in the Treatment of Pancreatic Adenocarcinoma: a Retrospective Cohort Study.Molecular imaging and biology · 2021Article
- SupplementalCancers · 2021Article
- Peripheral Nerve Nanoimaging: Monitoring Treatment and Regeneration.The AAPS journal · 2017Review
- FDG Whole-Body PET/MRI in Oncology: a Systematic Review.Nuclear medicine and molecular imaging · 2017Review
- Clinical Utility of Positron Emission Tomography Magnetic Resonance Imaging (PET-MRI) in Gastrointestinal Cancers.Diagnostics (Basel, Switzerland) · 2016Review
- Article
- [(18)F]FDG PET/MRI vs. PET/CT for whole-body staging in patients with recurrent malignancies of the female pelvis: initial results.European journal of nuclear medicine and molecular imaging · 2015Article
- Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer.World journal of gastroenterology · 2014Review
- Quantitative multimodality imaging in cancer research and therapy.Nature reviews. Clinical oncology · 2014Review
- Prospective evaluation of the clinical utility of 18-fluorodeoxyglucose PET CT scanning in patients with von hippel-lindau-associated pancreatic lesions.Journal of the American College of Surgeons · 2014Article
- Noninvasive imaging of peripheral nerves.Cells, tissues, organs · 2014Review
- Does the novel integrated PET/MRI offer the same diagnostic performance as PET/CT for oncological indications?PloS one · 2014Article
- The role ofJournal of radiation oncology · 2013Article
- Article
- Simultaneous PET-MRI in oncology: a solution looking for a problem?Magnetic resonance imaging · 2012Review
- State-of-the-art PET/CT of the pancreas: current role and emerging indications.Radiographics : a review publication of the Radiological Society of North America, IncArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo demonstrate that positron emission tomography (PET)/magnetic resonance imaging (MRI) fusion was feasible in characterizing pancreatic tumors (PTs), comparing MRI and computed tomography (CT) as mapping images for fusion with PET as well as fused PET/MRI and PET/CT.
methodsWe retrospectively reviewed 47 sets of (18)F-fluorodeoxyglucose ((18)F -FDG) PET/CT and MRI examinations to evaluate suspected or known pancreatic cancer. To assess the ability of mapping images for fusion with PET, CT (of PET/CT), T1- and T2-weighted (w) MR images (all non-contrast) were graded regarding the visibility of PT (5-point confidence scale). Fused PET/CT, PET/T1-w or T2-w MR images of the upper abdomen were evaluated to determine whether mapping images provided additional diagnostic information to PET alone (3-point scale). The overall quality of PET/CT or PET/MRI sets in diagnosis was also assessed (3-point scale). These PET/MRI-related scores were compared to PET/CT-related scores and the accuracy in characterizing PTs was compared.
resultsForty-three PTs were visualized on CT or MRI, including 30 with abnormal FDG uptake and 13 without. The confidence score for the visibility of PT was significantly higher on T1-w MRI than CT. The scores for additional diagnostic information to PET and overall quality of each image set in diagnosis were significantly higher on the PET/T1-w MRI set than the PET/CT set. The diagnostic accuracy was higher on PET/T1-w or PET/T2-w MRI (93.0 and 90.7%, respectively) than PET/CT (88.4%), but statistical significance was not obtained.
conclusionPET/MRI fusion, especially PET with T1-w MRI, was demonstrated to be superior to PET/CT in characterizing PTs, offering better mapping and fusion image quality.
Indexed as
Identifiers
21347626What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.